Green Cross Medical Science Corporation (142280) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-160.64 Million ≈ $-108.86K USD) by net assets (₩46.60 Billion ≈ $31.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 142280 equity to assets ratio to measure how much of total assets are equity-financed.
Green Cross Medical Science Corporation - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Green Cross Medical Science Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 142280 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Green Cross Medical Science Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Green Cross Medical Science Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Choice Development Inc
TW:9929
|
0.058x |
|
Kishin Corporation
KO:092440
|
0.004x |
|
Central Petroleum Ltd
AU:CTP
|
0.120x |
|
DPS Resources Bhd
KLSE:7198
|
-0.014x |
|
City Of London Investment Trust
LSE:CTY
|
0.005x |
|
AS Ekspress Grupp
F:DYC
|
-0.002x |
|
Taihan Precision Technology Co Ltd
TWO:1336
|
0.055x |
|
Shemaroo Entertainment Limited
NSE:SHEMAROO
|
0.120x |
Annual Cash Flow Conversion Efficiency for Green Cross Medical Science Corporation (2014–2025)
The table below shows the annual cash flow conversion efficiency of Green Cross Medical Science Corporation from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 142280 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩46.37 Billion ≈ $31.42 Million |
₩7.20 Billion ≈ $4.88 Million |
0.155x | +74.72% |
| 2024-12-31 | ₩41.21 Billion ≈ $27.93 Million |
₩3.66 Billion ≈ $2.48 Million |
0.089x | -22.67% |
| 2023-12-31 | ₩36.92 Billion ≈ $25.02 Million |
₩4.24 Billion ≈ $2.87 Million |
0.115x | -64.89% |
| 2022-12-31 | ₩33.25 Billion ≈ $22.54 Million |
₩10.88 Billion ≈ $7.37 Million |
0.327x | +164.94% |
| 2021-12-31 | ₩36.11 Billion ≈ $24.47 Million |
₩-18.20 Billion ≈ $-12.33 Million |
-0.504x | -224.76% |
| 2020-12-31 | ₩56.47 Billion ≈ $38.27 Million |
₩-8.76 Billion ≈ $-5.94 Million |
-0.155x | -87.24% |
| 2019-12-31 | ₩49.58 Billion ≈ $33.60 Million |
₩-4.11 Billion ≈ $-2.78 Million |
-0.083x | -146.02% |
| 2018-12-31 | ₩15.34 Billion ≈ $10.40 Million |
₩-516.61 Million ≈ $-350.10K |
-0.034x | -125.18% |
| 2017-12-31 | ₩23.23 Billion ≈ $15.75 Million |
₩3.11 Billion ≈ $2.11 Million |
0.134x | -64.95% |
| 2016-12-31 | ₩26.85 Billion ≈ $18.20 Million |
₩10.25 Billion ≈ $6.94 Million |
0.382x | +302.32% |
| 2015-12-31 | ₩28.87 Billion ≈ $19.56 Million |
₩-5.45 Billion ≈ $-3.69 Million |
-0.189x | -167.97% |
| 2014-12-31 | ₩31.50 Billion ≈ $21.35 Million |
₩-2.22 Billion ≈ $-1.50 Million |
-0.070x | -- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more